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To assess herd immunity to swine inﬂ  uenza viruses, 
we determined antibodies in 28 paired serum samples from 
participants in a prospective serologic cohort study in Hong 
Kong who had seroconverted to pandemic (H1N1) 2009 
virus. Results indicated that infection with pandemic (H1N1) 
2009 broadens cross-reactive immunity to other recent 
subtype H1 swine viruses. 
P
andemic (H1N1) 2009 was able to spread globally 
because it was antigenically divergent from 
contemporary human seasonal subtype H1N1 inﬂ  uenza 
viruses (1). Because we now recognize that pandemics 
can arise from inﬂ   uenza subtypes endemic in humans, 
it is essential that subtypes, H1 and H3 swine viruses be 
considered potential future pandemic candidates, together 
with other avian virus subtypes such as H2, H5, or H9. 
Thus, it becomes imperative to investigate herd immunity 
in humans to swine and avian inﬂ  uenza viruses of subtypes 
H1 and H3.
Inﬂ   uenza virus subtypes H1 and H3 of diverse 
lineages are endemic in swine and are globally widespread. 
Eurasian avian-like swine H1 viruses are found in Europe; 
triple reassortant swine subtypes H1 and H3 viruses 
remain entrenched in North America (2). In China, we 
have demonstrated the co-circulation of these lineages 
together with classical swine (CS) subtype H1 viruses and 
also documented the emergence of antigenically variant 
reassortant viruses with gene segments of >2 of these 
lineages. We previously showed a lack of herd immunity 
in humans to some of these swine virus lineages in serum 
samples collected before the 2009 pandemic (3). However, 
the spread of pandemic (H1N1) 2009 worldwide may 
generate cross-reactive herd immunity to some of these 
swine virus lineages, making them less likely candidates 
for future pandemics. In this study, we assessed the 
relationship between seroconversion to pandemic (H1N1) 
2009 and cross-reactive antibody responses to other major 
subtype H1 swine viruses in humans.  
The Study
Twenty-eight paired serum samples from a prospective 
serologic cohort study in Hong Kong, in which participants 
seroconverted to the pandemic (H1N1) 2009 virus, were 
selected to represent persons of diverse ages (median 39.5 
years, range 8–74 years). Details of the serologic cohort 
have been reported elsewhere (4). The ﬁ  rst (prepandemic 
or baseline) serum sample from each person was collected 
during July–August 2009, and the second (postpandemic 
or convalescent-phase) serum sample was collected during 
November 2009–February 2010. The peak of the ﬁ  rst 
pandemic wave in Hong Kong occurred in September 
2009. Subtype H1 swine inﬂ  uenza viruses, representative 
of CS, Eurasian avian-like swine (EA), triple reassortant 
swine (TRIG), pandemic (H1N1) 2009 viruses, and 
selected reassortants between these lineages with diverse 
antigenic proﬁ  les, were selected from our surveillance of 
swine inﬂ  uenza viruses in China (3). Relevant viruses from 
other geographic regions were also included. Each pair of 
baseline and convalescent-phase serum samples was tested 
for antibodies by microneutralization tests using each 
swine inﬂ  uenza virus. The proﬁ  le of serologic responses to 
these swine viruses is shown in the Figure.
In accordance with our selection criteria, all 28 persons 
seroconverted (rise in antibody titer from <20 to >40) to 
the pandemic (H1N1) 2009 virus; follow-up antibody 
titers ranged from 40 to 320 (Figure). As expected, no 
serologic response occurred to seasonal inﬂ  uenza (H1N1) 
virus A/HK/400599/2008. Because the postpandemic 
serum samples were collected 2–5 months after the peak 
of the pandemic, waning of antibody titers over a few 
months is expected to be relatively modest (5). Notably, 
although few of the prepandemic serum samples tested 
had evidence of antibody titers >40 to any of the swine 
H1 viruses, the convalescent-phase serum sample of most 
persons had detectable antibody titers to other inﬂ  uenza 
viruses: CS (H1N1) Sw4167 (93% seropositive at a titer 
of >40; geometric mean titer [GMT] 121.9) and Sw1304 
(86%; GMT 107.7); TRIG Sw1110 (75%; GMT 50); EA 
SwNS29 (46%; GMT 40), and an antigenically variant EA 
virus from Hong Kong that had acquired a nonstructural 
gene segment from TRIG virus by reassortment (57%; 
GMT 53) (Table). 
Because Hong Kong is a heavily urbanized 
environment, exposure of the study volunteers to live 
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the seroconversion to swine inﬂ   uenza viruses observed 
is not likely to be caused by infection with other swine 
inﬂ   uenza viruses. Notably, only 11% of these persons 
had neutralizing antibody titers to the EA virus SwG112, 
isolated in Ghent, Belgium. The difference between the 
EA viruses in Asia and Europe in this regard is worthy 
of further study. Because the hemagglutinin of EA virus 
is of avian origin, it is expected to cross-react poorly 
with subtype H1 of human or CS (derived from the 1918 
pandemic H1 virus) derivation. What was unexpected was 
the observation that EA viruses isolated in China appear to 
manifest greater serologic cross-reactivity with pandemic 
(H1N1) 2009. Notably, little cross-reactivity occurred to 2 
avian subtype H1 viruses isolated from wild birds in Hong 
Kong (data not shown). 
A Poisson regression model of age as an indication 
of exposure for titer was used to look for evidence of age 
effects in both baseline and follow-up serum samples. The 
raw titers t (from the scale [<20, 20, 40, 80, …]) were 
transformed to outcome variable x (from the scale [0, 1, 2, 3, 
…]) in the following way: ﬁ  rst, values of <20 were assigned 
the value of 10. Second, titers were divided by 10 and the 
logarithm taken (base 2). We used an uncorrected 95% 
statistical signiﬁ  cance to test for preliminary evidence of an 
age effect. In the prepandemic serum samples, increasing 
age was signiﬁ  cantly associated with increased antibody 
titers for pandemic (H1N1) 2009 (0.087; 95% conﬁ  dence 
interval [CI] 0.002–0.720) and for TRIG virus 1110 (0.036; 
95% CI 0.0009–0.062). Conversely, a signiﬁ  cant negative 
relation with age for seasonal subtype H1N1 virus was 
found (−0.039; 95% CI −0.057 to −0.022). No signiﬁ  cant 
age effects were found for other viruses. This age effect 
was lost in postpandemic infection serum samples, with the 
exception of antibody titers to the seasonal subtype H1N1 
virus, which still had a negative association with age.
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Figure. Neutralizing antibody titers to subtype H1 swine inﬂ  uenza viruses of the classical swine, North American triple reassortant, and 
Eurasian avian-like swine lineages in baseline (prepandemic [pre]) and convalescent-phase (postpandemic [post]) serum samples from 
28 persons who seroconverted to pandemic (H1N1) 2009 infection, Hong Kong. Complete details on the serologic study cohort from which 
this subset is drawn are from (4). The pandemic A/California/4/2009 (H1N1) and seasonal inﬂ  uenza A/HK/400599/2008 (H1N1) viruses 
were used as controls. Orange lines indicate geometric mean titer; green error bars indicate 95% conﬁ  dence intervals. *p<0.05; †p<0.01.
Table. Seroprevalence and GMT for swine influenza viruses of H1 subtype in prepandemic and postpandemic serum specimens from 






No. (%) seroconverters†  GMT 
Prepandemic Postpandemic Prepandemic   Postpandemic
A/California/4/2009 (H1N1)  Cal4 Pandemic (Pdm)  0 28 (100)  10.77  107.7 
A/Swine/HK/4167/1999 (H1N1)  Sw4167  Classical swine 
(CS) 
6 (21)  26 (93)  17.24  121.9 
A/Swine/HK/1304/2003 (H1N?)  Sw1304  Classical swine 
reassortant (CSr) 
7 (25)  24 (86)  16.41  105
A/Swine/HK/1110/2006 (H1N2)  Sw1110  Triple reassortant 
(TRIG) 
2 (7)  21 (75)  13.13  44.16 
A/Swine/HK/NS29/2009 (H1N1)  SwNS29  Eurasian avian-like 
(EA)
2 (7)  13 (46)  12.50  30.46 
A/Swine/HK/1559/2008 (H1N1)  Sw1559  Eurasian avian-like 
reassortant (EAr) 
2 (7)  16 (57)  12.81  41.00 
A/Swine/G/112/2007 (H1N1)  Sw112  Eurasian avian-like 
(EA)
0 (0)  3 (11)  10.25  13.13 
A/Swine/HK/201/2010 (H1N1)  Sw201  TRIG reassortant 
(TRIGr) 
3 (11)  21 (75)  12.2 48.76 
A/HK/400599/2008 (H1N1)  400599  Seasonal influenza  12 (43)  12 (43)  38.07  40.00 
*GMT, geometric mean titer. 
†Seroconverters were persons with antibody titer >40.  Immunity to Swine Inﬂ  uenza Viruses
Conclusions 
In this study, we focused on deﬁ  ning the effects of 
seroconversion to pandemic (H1N1) 2009 on serologic 
cross-reactivity to other swine subtype H1 viruses. The 
next step should be to ascertain herd immunity to these 
swine inﬂ   uenza viruses in different population groups. 
We chose not to do this at this stage because the pandemic 
virus is still circulating among human populations, and 
seroprevalence is likely to continue to increase in different 
age groups over the next few years. Therefore, studying 
the effect of seroconversion to pandemic (H1N1) 2009 
on cross-reaction to other swine inﬂ  uenza viruses would 
provide more meaningful information at this stage.
The results of our study suggest that the spread of 
pandemic (H1N1) 2009 in the population is broadening the 
serologic cross-reactivity and immunity in humans to other 
swine inﬂ  uenza viruses. However, gaps in immunity to 
selected swine inﬂ  uenza subtype H1 viruses remain (e.g., 
Sw112), at least as ascertained by neutralization antibody 
titers. We recognize, however, that neutralization tests do 
not capture all aspects of herd immunity in a population. 
Thus, our ﬁ  ndings only serve to focus attention on the need 
for further study of population immunity to viruses such 
as Sw112. In general, these ﬁ  ndings highlight the need for 
enhanced global surveillance of swine inﬂ  uenza viruses 
for the systematic assessment of human herd immunity 
to novel swine strains and to facilitate the development 
of routine (evidence-based) procedures for the ranking of 
known strains in terms of their pandemic risk. 
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